VectivBio Holding AG

As of June 29, 2023, VectivBio Holding AG was acquired by Ironwood Pharmaceuticals, Inc. VectivBio Holding AG, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes medicines to treat severe gastrointestinal conditions. The company’s product apraglutide currently undergoes Phase III clinical trials for the treatment of patients suffers from short bowel syndrome-intestinal failure (SBS-IF). Additionally, it participates in Phase II clinical trials for SBS-IF in patients with colon-in-continuity anatomy and for patients with steroid-refractory gastrointestinal acute graft versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland.